Capricor Therapeutics, Inc. News: Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
Capricor Therapeutics, Inc. News: Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
Quarter Ended Jun 30, 2024
For Fiscal Year Ending Dec 31, 2023
Sign up today and receive company updates straight to your inbox.
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor’s lead candidate, deramiocel (CAP-1002), is an allogeneic cell therapy that is currently in Phase 3 clinical development for treating Duchenne muscular dystrophy. Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor’s current focus is on developing exosomes capable of delivering nucleic acids as well as proteins to treat or prevent a variety of diseases.
Capricor Therapeutics, Inc.
10865 Road to the Cure
Suite 150
San Diego, CA 92121
United States
T: 858-727-1755
Equiniti Trust Company, LLC
48 Wall Street, Floor 23
New York, NY 10005
United States
https://equiniti.com/us/